Shares of Osiris Therapeutics currently reflect the impact of delayed financials and the associated delisting from Nasdaq. Just as Osiris tells us to expect better from regenerative medicine. I expect ...
Osiris Therapeutics Inc. rose the most in 19 months in Nasdaq Stock Market trading after Genzyme Corp. agreed to pay the company as much as $1.38 billion to develop two experimental drugs using adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback